EUVIMEDSkopri EUVIMED
Randomisierte kontrollierte StudieOpen access · CC BY-NC 4.0

Cream versus ointment: Randomized single‐blinded study on the adherence to treatment with topical methylprednisolone aceponate

Deborah Maria Gregersen iD, Melanie Peckruhn, Maria Breternitz-Gruhne, Isabella Schiller, Ulrike Schumacher iD, Lisa Franke, Viola Bahr, Jörg Tittelbach, Peter Elsner iD

Contact Dermatitis · 2024-02 · 90 (2) · 161-168

DOI: 10.1111/cod.14447 ↗

At a glance

Randomisierte kontrollierte Studie in Contact Dermatitis, published online on 2023-11-13. Written by Deborah Maria Gregersen and 8 co-authors. Institution: Department of Dermatology, University Hospital Jena, Jena, Germany. Major MEDLINE topics: Dermatitis, Allergic Contact, Eczema. Cited 5 times so far (Crossref); 21 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Bayer Consumer Care AG.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background

Overall adherence in the treatment of chronic dermatoses is poor. Textbooks state an adherence dependence on galenics. Trial Design Prospective, randomized, parallel‐grouped, single‐blinded (investigator), monocentric clinical trial (phase IV) on the adherence to treatment of chronic mild to moderate hand eczema with topical methylprednisolone aceponate (MPA, Advantan®) in different vehicles. Objectives and Endpoints Primary objective was the assessment of the adherence depending on vehicle type in patients with chronic hand eczema. Secondary objective was improvement after a 4‐week treatment period. Primary Endpoint Adherence is defined as the percentage of patients applying at least aimed daily dose. Prescribed daily dose was defined as the planned number of applications per day (1) * surface (measured) * aimed amount per application (mg/cm 2 ). Truly applicated daily dose was evaluated as individual mean amount per dose * individual mean number of applications per day. Adherence was assumed, if truly applicated daily dose is at least 75% of the prescribed daily dose and the individual mean number of applications per day is at least 0.85. Secondary Endpoint Efficacy was measured by improvement of Hand Eczema Severity Index (HECSI) and Investigator's Global Assessment (IGA) after a 4‐week treatment period and in addition to Quality of Life in Hand Eczema Questionnaire (QOLHEQ) and Visual Analogue Scale (VAS) to assess pruritus.

Methods

Number of participants randomized to each group 40, 80 total. Group 1 MPA‐C: Methylprednisolone aceponate 0.1% cream and barrier repair emollient (Bepanthen® Sensiderm). Group 2 MPA‐FO: Methylprednisolone aceponate 0.1% fatty ointment and barrier repair emollient (Bepanthen® Sensiderm). Adherence to treatment was compared via Fisher's exact test.

Results

Of the patients, 48% were adherent according to our definition. There was no significant difference between MPA‐C (42.1%) and MPA‐FO (54.1%; p = 0.36; group difference—12.0%, 95% CI—34.3%–11.5%). Generalized‐linear‐model‐analysis of adherence to study treatment with factors emollient use, treatment, time and treatment‐time interaction showed a parallel between adherence and amount of emollient use (odds ratio 1.74, p = 0.0038; 95% CI—1.22–2.52). Improvement of hand eczema was seen according to clinical scores without remarkable differences between the groups.

Conclusions

No dependence of adherence on galenics of topical treatment of chronic hand eczema could be proved. Patients who use more emollient tend to be more adherent to the topical treatment.

Subjects

MeSH terms (MEDLINE)

Dermatitis, Allergic ContactEczemaHumansEmollientsOintmentsQuality of LifeProspective StudiesMethylprednisoloneTreatment OutcomePantothenic Acid

Author keywords

adherencechronic hand eczemagalenics

Substances

methylprednisolone aceponateEmollientsOintmentsdexpanthenolMethylprednisolonePantothenic Acid

Authors and institutions

  • Department of Dermatology, University Hospital Jena, Jena, Germany.
  • Center for Clinical Studies, University Hospital Jena, Jena, Germany.

ORCID profiles: Deborah Maria Gregersen, Ulrike Schumacher, Peter Elsner

Funding

  • Bayer Consumer Care AG

Cite

APA

Gregersen, D. M., Peckruhn, M., Breternitz-Gruhne, M., Schiller, I., Schumacher, U., Franke, L., Bahr, V., Tittelbach, J., & Elsner, P. (2024). Cream versus ointment: Randomized single‐blinded study on the adherence to treatment with topical methylprednisolone aceponate. Contact Dermatitis, 90(2), 161-168. https://doi.org/10.1111/cod.14447

Vancouver

Gregersen DM, Peckruhn M, Breternitz-Gruhne M, Schiller I, Schumacher U, Franke L, et al. Cream versus ointment: Randomized single‐blinded study on the adherence to treatment with topical methylprednisolone aceponate. Contact Dermatitis. 2024;90(2):161-168. doi:10.1111/cod.14447

BibTeX
@article{Gregersen2024,
  author = {Gregersen, Deborah Maria and Peckruhn, Melanie and Breternitz-Gruhne, Maria and Schiller, Isabella and Schumacher, Ulrike and Franke, Lisa and Bahr, Viola and Tittelbach, Jörg and Elsner, Peter},
  title = {Cream versus ointment: Randomized single‐blinded study on the adherence to treatment with topical methylprednisolone aceponate},
  journal = {Contact Dermatitis},
  year = {2024},
  volume = {90},
  number = {2},
  pages = {161--168},
  doi = {10.1111/cod.14447}
}
Start for free →